TOP TEN perturbations for 1552639_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552639_at
Selected probe(set): 236285_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552639_at (236285_at) across 6672 perturbations tested by GENEVESTIGATOR:

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):5.3078823
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (ductal and lobular carcinoma; primary)

Relative Expression (log2-ratio):5.2977457
Number of Samples:2 / 4
Experimental expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).
Control expO breast cancer study 1 (ductal and lobular carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with ductal and lobular carcinoma.

expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (lobular carcinoma, NOS; primary)

Relative Expression (log2-ratio):5.004181
Number of Samples:2 / 39
Experimental expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).
Control expO breast cancer study 1 (lobular carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with lobular carcinoma (NOS).

expO breast cancer study 1 (ductal and lobular carcinoma; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):-4.923402
Number of Samples:4 / 2
Experimental expO breast cancer study 1 (ductal and lobular carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with ductal and lobular carcinoma.
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.

expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal carcinoma; in situ)

Relative Expression (log2-ratio):4.8162737
Number of Samples:2 / 3
Experimental expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).
Control expO breast cancer study 1 (intraductal carcinoma; in situ)
Tumor tissue samples obtained from the breast of patients with intraductal carcinoma.

expO breast cancer study 1 (mucocarcinoid tumor, malignant; primary) / expO breast cancer study 1 (medullary carcinoma, NOS; primary)

Relative Expression (log2-ratio):-4.7395144
Number of Samples:6 / 2
Experimental expO breast cancer study 1 (mucocarcinoid tumor, malignant; primary)
Primary tumor tissue samples obtained from the breast of patients with malignant mucocarcinoid tumor.
Control expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):4.658124
Number of Samples:2 / 3
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal adult kidney tissue samples.

expO breast cancer study 1 (lobular carcinoma, NOS; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):-4.629837
Number of Samples:39 / 2
Experimental expO breast cancer study 1 (lobular carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with lobular carcinoma (NOS).
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.

cysteine deprivation study 1 (long) / non-deprivated C3A/HepG2 cell sample

Relative Expression (log2-ratio):4.609825
Number of Samples:3 / 3
Experimental cysteine deprivation study 1 (long)
C3A/HepG2 cells were cultured in sulfur amino acid-free DMEM supplemented only with 0.1 mM methionine (cysteine-free medium) for 42h.
Control non-deprivated C3A/HepG2 cell sample
C3A/HepG2 cells were cultured in sulfur amino acid-free DMEM supplemented with 0.1 mM methionine + 0.1 mM cysteine (complete medium) for 42h.

expO breast cancer study 1 (intraductal carcinoma; in situ) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):-4.44193
Number of Samples:3 / 2
Experimental expO breast cancer study 1 (intraductal carcinoma; in situ)
Tumor tissue samples obtained from the breast of patients with intraductal carcinoma.
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.